The Resource Genetic influences on response to drug treatment for major psychiatric disorders, Janusz K. Rybakowski, Alessandro Serretti, editors

Genetic influences on response to drug treatment for major psychiatric disorders, Janusz K. Rybakowski, Alessandro Serretti, editors

Label
Genetic influences on response to drug treatment for major psychiatric disorders
Title
Genetic influences on response to drug treatment for major psychiatric disorders
Statement of responsibility
Janusz K. Rybakowski, Alessandro Serretti, editors
Contributor
Editor
Subject
Language
eng
Cataloging source
N$T
Dewey number
616.89
Index
no index present
LC call number
RC435
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Label
Genetic influences on response to drug treatment for major psychiatric disorders, Janusz K. Rybakowski, Alessandro Serretti, editors
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references
http://library.link/vocab/branchCode
  • net
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Introduction; Contents; Chapter 1: Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia; 1.1 Introduction; 1.1.1 Pharmacogenetics of Antipsychotic Efficacy; 1.1.2 Clinical Response Phenotypes; 1.1.3 Research Strategies; 1.2 Pharmacogenetic and Pharmacogenomic Findings; 1.2.1 Candidate Gene Studies; 1.2.1.1 Findings Related to Antipsychotic Efficacy; Findings in Targeted Neurotransmitters and Transporters; Findings in Metabolic Enzymes; Others; 1.2.1.2 Findings Related to Antipsychotic-Induced Side Effects; Findings in Targeted Neurotransmitter Receptors and Transporters
  • 2.2.1.2 Neurotransmitter GenesDopamine System Genes; Serotonin System Genes; 2.2.1.3 Oxidative Stress Genes; 2.2.1.4 Other Genes; The Brain-Derived Neurotrophic Factor (BDNF); Cannabinoid Receptor 1 (CNR1); Dipeptidyl Peptidase-Like Protein 6 (DPP6); Heparan Sulphate Proteoglycan 2 (HSPG2), Perlecan; 2.2.2 Antipsychotic-Induced Weight Gain (AIWG); 2.2.2.1 Neurotransmitter Genes; Serotonin System Genes; Dopamine System Genes; 2.2.2.2 Leptin and Leptin Receptor; 2.2.2.3 The Melanocortin 4 Receptor (MC4R); 2.2.2.4 The Cannabinoid Receptor 1 (CNR1) and the Neuropeptide Y (NPY) Genes
  • 2.2.2.5 Mitochondrial Genes2.2.2.6 Other Genes; 2.2.3 Clozapine-Induced Agranulocytosis (CIA); 2.3 Summary; References; Chapter 3: Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs; 3.1 Introduction; 3.1.1 Candidate Gene Studies; 3.1.1.1 Monoaminergic System; Serotonin Transporter; Serotonin Receptors; Enzymes Responsible for Monoamine Metabolism; 3.1.1.2 Glutamatergic System; 3.1.1.3 Neuroplasticity; 3.1.1.4 Inflammation; Cytokines; HPA Axis; 3.1.1.5 Antidepressant Pharmacokinetics; Cytochrome P450 Genes; ABCB1 Gene; 3.1.2 Genome-Wide Association Studies (GWAS)
  • 3.2 Clinical Applicability3.3 Conclusion; References; Chapter 4: Genomic Studies of Treatment Resistance in Major Depressive Disorder; 4.1 Background and Motivation; 4.2 Rationale for Genetic Investigation; 4.3 Association Studies of TRD; 4.4 Treatment Outcomes in TRD Cohorts; 4.5 Clinical Status; 4.6 Challenges and Future Directions; References; Chapter 5: Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression; 5.1 Introduction; 5.2 Blood-Based Biomarkers; 5.2.1 Inflammation; 5.2.1.1 Predicting Treatment Response; 5.2.2 HPA Axis
  • Findings in Metabolic EnzymesOthers; 1.2.2 Genome-Wide Association Studies (GWAS); 1.2.2.1 Findings Related to Antipsychotic Efficacy; 1.2.2.2 Findings Related to Antipsychotic Side Effects; 1.3 Clinical Applications and Benefits of Pharmacogenetic Interventions; 1.3.1 Pharmacogenetic Findings as Biomarkers of Clinical Outcome; 1.3.2 Pharmacogenetic Tests for Prediction of Antipsychotic Response; 1.4 Conclusions; References; Chapter 2: Pharmacogenetics of Serious Antipsychotic Side Effects; 2.1 Background; 2.2 Common Side Effects; 2.2.1 Tardive Dyskinesia; 2.2.1.1 Drug Metabolism Genes
Control code
ocn937392399
Dimensions
unknown
Extent
1 online resource
File format
unknown
Form of item
online
Isbn
9783319270401
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-3-319-27040-1
Quality assurance targets
unknown
http://library.link/vocab/recordID
.b35313961
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)937392399
  • springer3319270389

Library Locations

    • Deakin University Library - Geelong Waurn Ponds CampusBorrow it
      75 Pigdons Road, Waurn Ponds, Victoria, 3216, AU
      -38.195656 144.304955
Processing Feedback ...